This episode breaks down how Congress is turning biotechnology into a core national security priority. John Stanford explains the biggest shifts in the 2025 defense bill, why China-focused guardrails are expanding, and how new investment rules could reshape biotech funding. We also cover a new bipartisan proposal to create a government-backed investment fund, and a high-stakes battle over ACA subsidies.
What NDAA change do you think will impact biotech most?
Should the U.S. invest directly in emerging biotechnologies?
How should policymakers balance security with scientific innovation?
If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:
https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/
https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true
Timestamps:
0:00 Disclaimers & Intro
0:23 NDAA Overview and Why It Matters
1:54 Biotech as a Strategic National Security Capability
2:54 Domestic Biomanufacturing & Supply Chain Priorities
3:19 DoD Bioindustrial Base & New Biotech Office
4:34 Data Standardization, AI Readiness & Security
5:07 Guarding the U.S. Biotech Ecosystem from China
7:09 Intelligence Community’s New Biotech Role
8:00 Outbound Investment Regime Explained
10:12 Implications for Investors & Biotech Leaders
12:42 The Independence Investment Fund Act
14:37 Why Congress Wants a Government-Backed Biotech Fund
14:40 Senate Showdown on ACA Subsidies & Healthcare Costs
17:36 Why Access and Innovation Are Interconnected
18:17 Closing Thoughts & Call for Questions
DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.
